Positive Results Presented from Proof-of-Concept Phase II Clinical Trial of Incyte Corporation's Oral JAK1 Inhibitor in Patients With Active Rheumatoid Arthritis

Published: Oct 29, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN DIEGO--(BUSINESS WIRE)--Incyte Corporation (Nasdaq: INCY) announced results from a 12-week, placebo-controlled, dose-escalation Phase II proof-of-concept clinical trial involving 60 patients with active rheumatoid arthritis for its proprietary oral JAK1 inhibitor. These results were presented today at the 2013 American College of Rheumatology / Association of Rheumatology Health Professionals (ACR/ARHP) Annual Scientific Meeting being held in San Diego, CA, from Oct. 25 to 30, 2013.

Help employers find you! Check out all the jobs and post your resume.

Back to news